Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia

G. Schiller, M. Lee, M. Territo, J. Gajewski, S. Nimer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although combination chemotherapy induces complete remission in 60-90% of adults with acute lymphoblastic leukemia, only 20-45% of patients remain in continued remission 5 years from diagnosis. For patients with a short first remission, multiple relapses, or patients with disease refractory to initial induction chemotherapy, few salvage treatments are successful. To improve the results of salvage therapy we studied the efficacy and toxicity of a combination of etoposide (100 mg/m2 IV qd x 5), ifosfamide (1.5 g/m2/d x 5), and mitoxantrone (8 mg/m2/d IV x 3) in 11 adult patients with relapsed or refractory ALL. The median follow-up of all patients completing therapy is 208 days (30-484+ days). Eight of 11 (73%; 95% confidence interval 45-92%) achieved a complete remission, two patients failed to enter remission, and one patient died of multiorgan system failure shortly after receiving therapy. Median DFS is 96 days and median survival from remission is 234 days. Five patients who achieved CR subsequently relapsed with a median time to relapse of 80 days (50-151 days). Median time to granulocyte >.5 x 109/L was 28 days (21-46 days) and the median time to platelet recovery >20 x 109/L was 24 days (21-39 days). Although gastrointestinal toxicity was common, no patient developed severe cardiac, hepatic, pulmonary, or neurologic complications. These results demonstrate that the combination of etoposide, ifosfamide, and mitoxantrone can be used as an effective salvage therapy for patients with resistant ALL.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalAmerican Journal of Hematology
Volume43
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Mitoxantrone
Ifosfamide
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Salvage Therapy
Therapeutics
Recurrence
Induction Chemotherapy
Combination Drug Therapy
Granulocytes
Nervous System
Blood Platelets
Confidence Intervals

Keywords

  • combination chemotherapy
  • resistant ALL
  • salvage treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. / Schiller, G.; Lee, M.; Territo, M.; Gajewski, J.; Nimer, S.

In: American Journal of Hematology, Vol. 43, No. 3, 1993, p. 195-199.

Research output: Contribution to journalArticle

Schiller, G. ; Lee, M. ; Territo, M. ; Gajewski, J. ; Nimer, S. / Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. In: American Journal of Hematology. 1993 ; Vol. 43, No. 3. pp. 195-199.
@article{65474c93d4f54ce2b54d61fd0e53cf7a,
title = "Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia",
abstract = "Although combination chemotherapy induces complete remission in 60-90{\%} of adults with acute lymphoblastic leukemia, only 20-45{\%} of patients remain in continued remission 5 years from diagnosis. For patients with a short first remission, multiple relapses, or patients with disease refractory to initial induction chemotherapy, few salvage treatments are successful. To improve the results of salvage therapy we studied the efficacy and toxicity of a combination of etoposide (100 mg/m2 IV qd x 5), ifosfamide (1.5 g/m2/d x 5), and mitoxantrone (8 mg/m2/d IV x 3) in 11 adult patients with relapsed or refractory ALL. The median follow-up of all patients completing therapy is 208 days (30-484+ days). Eight of 11 (73{\%}; 95{\%} confidence interval 45-92{\%}) achieved a complete remission, two patients failed to enter remission, and one patient died of multiorgan system failure shortly after receiving therapy. Median DFS is 96 days and median survival from remission is 234 days. Five patients who achieved CR subsequently relapsed with a median time to relapse of 80 days (50-151 days). Median time to granulocyte >.5 x 109/L was 28 days (21-46 days) and the median time to platelet recovery >20 x 109/L was 24 days (21-39 days). Although gastrointestinal toxicity was common, no patient developed severe cardiac, hepatic, pulmonary, or neurologic complications. These results demonstrate that the combination of etoposide, ifosfamide, and mitoxantrone can be used as an effective salvage therapy for patients with resistant ALL.",
keywords = "combination chemotherapy, resistant ALL, salvage treatment",
author = "G. Schiller and M. Lee and M. Territo and J. Gajewski and S. Nimer",
year = "1993",
doi = "10.1002/ajh.2830430307",
language = "English (US)",
volume = "43",
pages = "195--199",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia

AU - Schiller, G.

AU - Lee, M.

AU - Territo, M.

AU - Gajewski, J.

AU - Nimer, S.

PY - 1993

Y1 - 1993

N2 - Although combination chemotherapy induces complete remission in 60-90% of adults with acute lymphoblastic leukemia, only 20-45% of patients remain in continued remission 5 years from diagnosis. For patients with a short first remission, multiple relapses, or patients with disease refractory to initial induction chemotherapy, few salvage treatments are successful. To improve the results of salvage therapy we studied the efficacy and toxicity of a combination of etoposide (100 mg/m2 IV qd x 5), ifosfamide (1.5 g/m2/d x 5), and mitoxantrone (8 mg/m2/d IV x 3) in 11 adult patients with relapsed or refractory ALL. The median follow-up of all patients completing therapy is 208 days (30-484+ days). Eight of 11 (73%; 95% confidence interval 45-92%) achieved a complete remission, two patients failed to enter remission, and one patient died of multiorgan system failure shortly after receiving therapy. Median DFS is 96 days and median survival from remission is 234 days. Five patients who achieved CR subsequently relapsed with a median time to relapse of 80 days (50-151 days). Median time to granulocyte >.5 x 109/L was 28 days (21-46 days) and the median time to platelet recovery >20 x 109/L was 24 days (21-39 days). Although gastrointestinal toxicity was common, no patient developed severe cardiac, hepatic, pulmonary, or neurologic complications. These results demonstrate that the combination of etoposide, ifosfamide, and mitoxantrone can be used as an effective salvage therapy for patients with resistant ALL.

AB - Although combination chemotherapy induces complete remission in 60-90% of adults with acute lymphoblastic leukemia, only 20-45% of patients remain in continued remission 5 years from diagnosis. For patients with a short first remission, multiple relapses, or patients with disease refractory to initial induction chemotherapy, few salvage treatments are successful. To improve the results of salvage therapy we studied the efficacy and toxicity of a combination of etoposide (100 mg/m2 IV qd x 5), ifosfamide (1.5 g/m2/d x 5), and mitoxantrone (8 mg/m2/d IV x 3) in 11 adult patients with relapsed or refractory ALL. The median follow-up of all patients completing therapy is 208 days (30-484+ days). Eight of 11 (73%; 95% confidence interval 45-92%) achieved a complete remission, two patients failed to enter remission, and one patient died of multiorgan system failure shortly after receiving therapy. Median DFS is 96 days and median survival from remission is 234 days. Five patients who achieved CR subsequently relapsed with a median time to relapse of 80 days (50-151 days). Median time to granulocyte >.5 x 109/L was 28 days (21-46 days) and the median time to platelet recovery >20 x 109/L was 24 days (21-39 days). Although gastrointestinal toxicity was common, no patient developed severe cardiac, hepatic, pulmonary, or neurologic complications. These results demonstrate that the combination of etoposide, ifosfamide, and mitoxantrone can be used as an effective salvage therapy for patients with resistant ALL.

KW - combination chemotherapy

KW - resistant ALL

KW - salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=0027322252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027322252&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830430307

DO - 10.1002/ajh.2830430307

M3 - Article

C2 - 8352235

AN - SCOPUS:0027322252

VL - 43

SP - 195

EP - 199

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -